iPS Cells & Regenerative Medicine– category –
-
FDA Approves Allogeneic Cell Therapy TREGZI for GVHD; New Advanced Cell Therapy Association Launches in Europe
RegMedNet UK Overview The FDA has approved Orca Bio's allogeneic cell therapy TREGZI (Orc-T®) for graft-versus-host disease (GVHD), based on positive Phase 3 Precision-T trial results, aiming to mitigate GVHD and reconstruct immunity. Si... -
HCA Healthcare Announces Promising Results for CRISPR Gene Therapy Exa-cel in Pediatric Sickle Cell Disease and Beta-Thalassemia Patients
HCA Healthcare USA Overview HCA Healthcare has announced findings from a New England Journal of Medicine study, sponsored by Vertex Pharmaceuticals, demonstrating that the CRISPR gene-editing therapy exa-cel shows promising results in pe... -
CRISPR’s First Clinical Evidence for HBV cccDNA Elimination, Prime Editing Advances to Inaugural Human Trial
CRISPR Medicine News USA Overview Precision Biosciences' PBGENE-HBV has demonstrated the first clinical evidence of eliminating viral cccDNA in chronic Hepatitis B patients, marking a significant milestone for CRISPR-based therapies in i... -
3D Bioprinted Organoids Pave the Way for Clinical Translation in Oncology, Regenerative Medicine, and Drug Discovery
Reproductive Biology (Oxford Academic) UK Overview 3D bioprinted organoids are demonstrating significant advances in oncology, regenerative medicine, and drug discovery by more faithfully replicating in vivo tissue structures and functio... -
Continuous Manufacturing and Automated Closed Systems Revolutionize Cell & Gene Therapy Production for Enhanced Efficiency and Quality
News-Medical.net UK Overview The commercial manufacturing of cell and gene therapies is being transformed by the imperative for continuous processing and automated closed systems to overcome current scalability and quality challenges. Th... -
iPS Cells & Regenerative Medicine Weekly Report June 28, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report June 28, 2026 (PDF) — Download Weekly Report June 28, 2026 (PDF) — DownloadDownload 🎙 Podcast June 28, 2026 (... -
Europe’s Regulatory Frontier for Advanced Biologics: Real-World Evidence and Patient Voices Shape Cell and Gene Therapies
ResearchGate (論文) Global Overview A new ResearchGate paper explores Europe's progressive regulatory landscape for advanced cell and gene therapies, a class of complex, engineered biologics. It underscores the critical role of integrati... -
Samsung Biologics Expands Bio R&D Center Beyond CDMO Support, Investing in Next-Gen Modalities, AI, and Machine Learning
Korea Biomedical Review (KBR) South Korea Overview Samsung Biologics is significantly expanding its Bio R&D Center beyond traditional Contract Development and Manufacturing Organization (CDMO) support. The company is focusing on thre... -
Long-Read DNA Sequencers Market to Accelerate by 2035 Amid Biopharma Quality Control Demand: Essential for CAR-T Genomic Evaluation
IndexBox News and Statistics Global Overview The long-read DNA sequencer market is projected for accelerated growth by 2035, driven by biopharmaceutical quality control demands, particularly the need for high-resolution genomic evaluatio... -
Top 10 Emerging Healthcare Technologies in 2026: CRISPR Gene Editing Established as Therapeutic Category, Regenerative Medicine Nearing Clinical Application
Slate USA Overview An article on 10 emerging healthcare technologies to watch in 2026 highlights that CRISPR gene editing is moving beyond the lab to become a bona fide therapeutic category. Additionally, regenerative medicine and stem c...
